Survival and Recurrence After Breast Cancer in BRCA1/2 Mutation Carriers

El‐Tamer, Mahmoud; Russo, Donna; Troxel, Andrea B.; Bernardino, Lourdes; Mazziotta, Robert; Estabrook, Alison; Ditkoff, Beth-Ann; Schnabel, Freya; Mansukhani, Mahesh

doi:10.1245/aso.2004.05.018

Cited by 57 publications

(28 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study of Rebbeck et al (2004) described above, the 105 women who underwent BPM were at risk for 557.36 person-years, giving a rate of onset of BC of 0.0036 per annum, similar to that for the general population shown in Figure 5. Furthermore, there seems to be no significant difference in survival rates after onset between BRCA1/2 mutation carriers and non-carriers (Verhoog et al, 1998(Verhoog et al, , 1999El-Tamer et al, 2004). From Hartmann et al (2001), we deduce an average annual mortality rate from BC of 0.00067 (2 events/2970 person-years) for mutation carriers who underwent BPM, which is also similar to the level in the general population.…”

Section: Treatment For Unaffected Carriers: Bilateral Prophylactic Masupporting

confidence: 56%

The genetics of breast and ovarian cancer IV: a model of breast cancer progression

Lu¹,

Macdonald

Waters

2010

Scandinavian Actuarial Journal

View full text Add to dashboard Cite

Gui et al. (2006), in Part III of a series of papers, proposed a dynamic family history model of breast cancer (BC) and ovarian cancer (OC) in which the development of a family history was represented explicitly as a transition between states, and then applied this model to life insurance and critical illness insurance. In this study, we extend the model to income protection insurance (IPI). In this paper, Part IV of the series, we construct and parameterise a semi-Markov model for the life history of a woman with BC, in which events such as diagnosis, treatment, recovery and recurrence are incorporated. In Part V, we then show: (a) estimates of premium ratings depending on genotype or family history; and (b) the impact of adverse selection under various moratoria on the use of genetic information.keywords Breast

show abstract

Section: Treatment For Unaffected Carriers: Bilateral Prophylactic Masupporting

confidence: 56%

The genetics of breast and ovarian cancer IV: a model of breast cancer progression

Lu¹,

Macdonald

Waters

2010

Scandinavian Actuarial Journal

View full text Add to dashboard Cite

show abstract

“…One study on Israeli women concluded that breast cancer specific rates of death are similar between carriers of a BRCA1/2 founder mutation and non-carriers, with the hazard ratio among BRCA1 carriers to be 0.76 and 95% confidence interval (CI) 0.45~1.30, P=0.31; and the hazard ratio among BRCA2 carriers to be 1.3 and 95% CI 0.80~2.15, P=0.28 (Rennert et al, 2007). Another two studies conducted in New York and Rotterdam presented the same negative results that breast cancer specific survival is similar between the mutation carriers and non-carriers in breast cancer patients and patients at high risk for breast cancer, respectively (El-Tamer et al, 2004;Brekelmans et al, 2006).…”

Section: Prognosismentioning

confidence: 88%

BRCA1/2 associated hereditary breast cancer

Teng

Zheng

Wang

2008

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Breast cancer is one of the leading causes of death in women today. Some of the patients are hereditary, with a large proportion characterized by mutation in BRCA1 and/or BRCA2 genes. In this review, we provide an overview of these two genes, focusing on their relationship with hereditary breast cancers. BRCA1/2 associated hereditary breast cancers have unique features that differ from the general breast cancers, including alterations in cellular molecules, pathological bases, biological behavior, and a different prevention strategy. But the outcome of BRCA1/2 associated hereditary breast cancers still remains controversial; further studies are needed to elucidate the nature of BRCA1/2 associated hereditary breast cancers.

show abstract

“…However, the question of poorer survival is still unresolved today. Some reports have failed to confirm this trend [20][21][22][23][24] (Table 1) and, as discussed by several authors [31][32][33], many of these studies which were not conducted in an outbred population, are subject to potential selection biases, particularly toward survival, i.e. the individual's vital status was not independent of the ascertainment.…”

Section: Introductionmentioning

confidence: 99%

Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review

Bonadona

Dussart-Moser

Voirin

et al. 2006

Breast Cancer Res Treat

View full text Add to dashboard Cite

Despite unfavourable tumour features, we found no evidence for poorer short-term survival in BRCA1 mutation carriers compared to non-carriers in this prospective population-based cohort. The high rate of BRCA1 carriers who received chemotherapy for their BC should question the positive impact of this treatment, as suggested by preclinical studies showing increased chemosensitivity of BRCA1-associated tumours.

show abstract

Survival and Recurrence After Breast Cancer in BRCA1/2 Mutation Carriers

Abstract: Breast cancer patients with BRCA1/2 mutations have a similar outcome as non-mutation carriers.

Cited by 57 publications

References 30 publications

The genetics of breast and ovarian cancer IV: a model of breast cancer progression

The genetics of breast and ovarian cancer IV: a model of breast cancer progression

BRCA1/2 associated hereditary breast cancer

Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review

Contact Info

Product

Resources

About